Market Research

Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2024-2030

Best Price Guarantee Length Publisher Published Date SKU
from $4,749 193 Pages 360iResearch January, 2024 IRE18418349
Best Price Guarantee
Price from $4,749
Length 193 Pages
Publisher 360iResearch
Published Date January, 2024
SKU IRE18418349

Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2024-2030


The Ankylosing Spondylitis Market size was estimated at USD 5.18 billion in 2023 and expected to reach USD 5.60 billion in 2024, at a CAGR 8.31% to reach USD 9.06 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Ankylosing Spondylitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ankylosing Spondylitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.

Market Segmentation & Coverage

This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug

Cimzia
  • Cosentyx
  • Enbrel
  • Humira
  • Remicade
  • Simponi
  • Type of Molecule

    Biologics
  • Small Molecules
  • Mechanism Of Action

    Cyclooxygenase Inhibitors
  • Tumor Necrosis Factor Inhibitors
  • Route Of Administration

    Oral
  • Parenteral
  • Dosage Forms

    Liquid
  • Solid
  • End User

    Clinics
  • Hospitals
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Ankylosing Spondylitis Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ankylosing Spondylitis Market?
    3. What are the technology trends and regulatory frameworks in the Ankylosing Spondylitis Market?
    4. What is the market share of the leading vendors in the Ankylosing Spondylitis Market?
    5. Which modes and strategic moves are suitable for entering the Ankylosing Spondylitis Market?


    Note: PDF & Excel + Online Access - 1 Year


    • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Ankylosing Spondylitis Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Increasing incidences of ankylosing spondylitis
    5.1.1.2. Growing awareness about diagnostics and treatments for the disease
    5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
    5.1.2. Restraints
    5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
    5.1.3. Opportunities
    5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
    5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
    5.1.4. Challenges
    5.1.4.1. Concerns related to patent expiration of already approved drugs
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Ankylosing Spondylitis Market, by Drug
    6.1. Introduction
    6.2. Cimzia
    6.3. Cosentyx
    6.4. Enbrel
    6.5. Humira
    6.6. Remicade
    6.7. Simponi
    7. Ankylosing Spondylitis Market, by Type of Molecule
    7.1. Introduction
    7.2. Biologics
    7.3. Small Molecules
    8. Ankylosing Spondylitis Market, by Mechanism Of Action
    8.1. Introduction
    8.2. Cyclooxygenase Inhibitors
    8.3. Tumor Necrosis Factor Inhibitors
    9. Ankylosing Spondylitis Market, by Route Of Administration
    9.1. Introduction
    9.2. Oral
    9.3. Parenteral
    10. Ankylosing Spondylitis Market, by Dosage Forms
    10.1. Introduction
    10.2. Liquid
    10.3. Solid
    11. Ankylosing Spondylitis Market, by End User
    11.1. Introduction
    11.2. Clinics
    11.3. Hospitals
    12. Americas Ankylosing Spondylitis Market
    12.1. Introduction
    12.2. Argentina
    12.3. Brazil
    12.4. Canada
    12.5. Mexico
    12.6. United States
    13. Asia-Pacific Ankylosing Spondylitis Market
    13.1. Introduction
    13.2. Australia
    13.3. China
    13.4. India
    13.5. Indonesia
    13.6. Japan
    13.7. Malaysia
    13.8. Philippines
    13.9. Singapore
    13.10. South Korea
    13.11. Taiwan
    13.12. Thailand
    13.13. Vietnam
    14. Europe, Middle East & Africa Ankylosing Spondylitis Market
    14.1. Introduction
    14.2. Denmark
    14.3. Egypt
    14.4. Finland
    14.5. France
    14.6. Germany
    14.7. Israel
    14.8. Italy
    14.9. Netherlands
    14.10. Nigeria
    14.11. Norway
    14.12. Poland
    14.13. Qatar
    14.14. Russia
    14.15. Saudi Arabia
    14.16. South Africa
    14.17. Spain
    14.18. Sweden
    14.19. Switzerland
    14.20. Turkey
    14.21. United Arab Emirates
    14.22. United Kingdom
    15. Competitive Landscape
    15.1. FPNV Positioning Matrix
    15.2. Market Share Analysis, By Key Player
    15.3. Competitive Scenario Analysis, By Key Player
    16. Competitive Portfolio
    16.1. Key Company Profiles
    16.1.1. Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
    16.1.2. Boehringer Ingelheim International GmbH
    16.1.3. Bristol-Myers Squibb
    16.1.4. Celltrion Healthcare Co.,Ltd.
    16.1.5. Eisai Co., Ltd
    16.1.6. Eli Lilly and Company
    16.1.7. Hetero Drugs Limited
    16.1.8. Novartis AG
    16.1.9. Reliance Life Sciences
    16.1.10. Samsung Bioepis Co., Ltd.
    16.1.11. Sandoz International GmbH
    16.1.12. Sanofi-Aventis Groupe S.A.
    16.1.13. Shanghai Pharmaceuticals Holding Co., Ltd.
    16.1.14. Trinity Biotech PLC
    16.1.15. Xian Janssen Pharmaceutical Ltd
    16.2. Key Product Portfolio
    17. Appendix
    17.1. Discussion Guide
    17.2. License & Pricing
    FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
    FIGURE 2. ANKYLOSING SPONDYLITIS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANKYLOSING SPONDYLITIS MARKET DYNAMICS
    FIGURE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
    FIGURE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2030 (%)
    FIGURE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
    FIGURE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
    FIGURE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
    FIGURE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 22. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 24. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 27. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 28. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023

    $4,749
    $5,749
    $6,749
    $8,749

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings